Access and Evidence Limits

Many regenerative claims are not supported in the transcript with controlled human trial data. The article says dramatic individual outcomes are presented as cases rather than controlled evidence. The strongest evidence is said to concern early detection, epigenetics and NAD-related pathways, and falling fertility trends. Several therapies discussed in the article remain outside standard U.S. practice, require overseas access, or lack large double-blind human trials. Regulatory access is described as a major constraint for some stem-cell, exosome, rapamycin, and investigational therapies. Advanced diagnostics and regenerative therapies are described as expensive, though the source argues costs may fall as technologies scale.